vs
Proto Labs Inc（PRLB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Proto Labs Inc的1.5倍（$207.3M vs $139.3M），Proto Labs Inc净利率更高（5.8% vs -62.0%，领先67.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.4%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.3%）
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PRLB vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.3M | $207.3M |
| 净利润 | $8.1M | $-128.6M |
| 毛利率 | 45.6% | — |
| 营业利润率 | 7.1% | -54.7% |
| 净利率 | 5.8% | -62.0% |
| 营收同比 | 10.4% | 25.9% |
| 净利润同比 | 125.4% | 3.5% |
| 每股收益（稀释后） | $0.29 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $139.3M | — | ||
| Q4 25 | $136.5M | $207.3M | ||
| Q3 25 | $135.4M | $159.9M | ||
| Q2 25 | $135.1M | $166.5M | ||
| Q1 25 | $126.2M | $139.3M | ||
| Q4 24 | $121.8M | $164.6M | ||
| Q3 24 | $125.6M | $139.5M | ||
| Q2 24 | $125.6M | $147.0M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $7.2M | $-180.4M | ||
| Q2 25 | $4.4M | $-115.0M | ||
| Q1 25 | $3.6M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $7.2M | $-133.5M | ||
| Q2 24 | $4.5M | $-131.6M |
| Q1 26 | 45.6% | — | ||
| Q4 25 | 44.2% | — | ||
| Q3 25 | 45.3% | — | ||
| Q2 25 | 44.3% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 42.7% | — | ||
| Q3 24 | 45.6% | — | ||
| Q2 24 | 45.0% | — |
| Q1 26 | 7.1% | — | ||
| Q4 25 | 5.0% | -54.7% | ||
| Q3 25 | 6.5% | -106.9% | ||
| Q2 25 | 3.7% | -64.8% | ||
| Q1 25 | 3.6% | -102.6% | ||
| Q4 24 | -1.2% | -74.3% | ||
| Q3 24 | 6.8% | -94.6% | ||
| Q2 24 | 4.8% | -79.1% |
| Q1 26 | 5.8% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 5.3% | -112.8% | ||
| Q2 25 | 3.3% | -69.0% | ||
| Q1 25 | 2.9% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 5.7% | -95.7% | ||
| Q2 24 | 3.6% | -89.5% |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.25 | $-1.28 | ||
| Q3 25 | $0.30 | $-1.81 | ||
| Q2 25 | $0.18 | $-1.17 | ||
| Q1 25 | $0.15 | $-1.57 | ||
| Q4 24 | $-0.01 | $-1.34 | ||
| Q3 24 | $0.29 | $-1.40 | ||
| Q2 24 | $0.18 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $124.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $683.1M | $-80.0M |
| 总资产 | $778.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $124.0M | — | ||
| Q4 25 | $128.1M | $421.0M | ||
| Q3 25 | $119.2M | $202.5M | ||
| Q2 25 | $103.2M | $176.3M | ||
| Q1 25 | $96.8M | $127.1M | ||
| Q4 24 | $103.1M | $174.0M | ||
| Q3 24 | $100.5M | $150.6M | ||
| Q2 24 | $112.9M | $480.7M |
| Q1 26 | $683.1M | — | ||
| Q4 25 | $673.9M | $-80.0M | ||
| Q3 25 | $664.7M | $9.2M | ||
| Q2 25 | $664.7M | $151.3M | ||
| Q1 25 | $656.8M | $144.2M | ||
| Q4 24 | $670.2M | $255.0M | ||
| Q3 24 | $680.0M | $346.8M | ||
| Q2 24 | $685.2M | $432.4M |
| Q1 26 | $778.6M | — | ||
| Q4 25 | $763.4M | $1.5B | ||
| Q3 25 | $756.9M | $1.2B | ||
| Q2 25 | $743.3M | $1.3B | ||
| Q1 25 | $737.5M | $1.3B | ||
| Q4 24 | $743.5M | $1.5B | ||
| Q3 24 | $753.8M | $1.5B | ||
| Q2 24 | $758.2M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 2.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $17.5M | — | ||
| Q4 25 | $16.5M | $-99.8M | ||
| Q3 25 | $29.1M | $-91.4M | ||
| Q2 25 | $10.6M | $-108.3M | ||
| Q1 25 | $18.4M | $-166.5M | ||
| Q4 24 | $17.3M | $-79.3M | ||
| Q3 24 | $24.8M | $-67.0M | ||
| Q2 24 | $14.4M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $8.4M | $-100.8M | ||
| Q3 25 | $25.0M | $-92.7M | ||
| Q2 25 | $9.1M | $-110.7M | ||
| Q1 25 | $17.1M | $-167.8M | ||
| Q4 24 | $16.5M | $-79.5M | ||
| Q3 24 | $23.2M | $-68.6M | ||
| Q2 24 | $10.2M | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | -48.6% | ||
| Q3 25 | 18.5% | -58.0% | ||
| Q2 25 | 6.7% | -66.5% | ||
| Q1 25 | 13.6% | -120.5% | ||
| Q4 24 | 13.5% | -48.3% | ||
| Q3 24 | 18.5% | -49.2% | ||
| Q2 24 | 8.2% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 3.3% | 1.4% |
| Q1 26 | 2.16× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.03× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 5.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.44× | — | ||
| Q2 24 | 3.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
